Red cell substitutes: An update
The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO 2 production, and circulatory dynamics in primates in the virtual absence of...
Gespeichert in:
Veröffentlicht in: | Annals of emergency medicine 1985-08, Vol.14 (8), p.798-803 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 803 |
---|---|
container_issue | 8 |
container_start_page | 798 |
container_title | Annals of emergency medicine |
container_volume | 14 |
creator | Gould, Steven A Sehgal, Lakshman R Rosen, Arthur L Sehgal, Hansa L Moss, Gerald S |
description | The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO
2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting. |
doi_str_mv | 10.1016/S0196-0644(85)80061-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76245269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196064485800615</els_id><sourcerecordid>76245269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotVZ_QnFWoovRm0ySSdyUUnxBQfCxDjPJDUTaTp1kBP-90wfdurqLc849936EjCncUqDy7h2oljlIzq-VuFEAkubiiAwp6DKXpYRjMjxYTslZjF8AoDmjAzLgwIQu2ZBcvqHLLC4WWezqmELqEsb7bLrKurWrEp6TE18tIl7s54h8Pj58zJ7z-evTy2w6z20hIeUVeu9rKUFDWdaeUQ2UFzVwEAheSe8LVVlBNRaqKCqvnVacW1da6rX1rBiRq93eddt8dxiTWYa4uataYdNFU0rGBZO6N4qd0bZNjC16s27Dsmp_DQWzAWO2YMzma6OE2YIxos-N9wVdvUR3SO1J9Ppkp2P_5U_A1kQbcGXRhRZtMq4J_zT8AVyfcJM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76245269</pqid></control><display><type>article</type><title>Red cell substitutes: An update</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</creator><creatorcontrib>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</creatorcontrib><description>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO
2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</description><identifier>ISSN: 0196-0644</identifier><identifier>EISSN: 1097-6760</identifier><identifier>DOI: 10.1016/S0196-0644(85)80061-5</identifier><identifier>PMID: 4025972</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Animals ; Blood Substitutes - metabolism ; Blood Substitutes - therapeutic use ; Drug Evaluation ; fluorocarbons ; Fluorocarbons - metabolism ; Fluorocarbons - therapeutic use ; hemorrhagic shock ; Humans ; Oxygen Consumption ; oxygen transport ; Papio ; polyhemoglobin ; Rats ; Shock, Hemorrhagic - drug therapy</subject><ispartof>Annals of emergency medicine, 1985-08, Vol.14 (8), p.798-803</ispartof><rights>1985 American College of Emergency Physicians</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</citedby><cites>FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0196-0644(85)80061-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4025972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gould, Steven A</creatorcontrib><creatorcontrib>Sehgal, Lakshman R</creatorcontrib><creatorcontrib>Rosen, Arthur L</creatorcontrib><creatorcontrib>Sehgal, Hansa L</creatorcontrib><creatorcontrib>Moss, Gerald S</creatorcontrib><title>Red cell substitutes: An update</title><title>Annals of emergency medicine</title><addtitle>Ann Emerg Med</addtitle><description>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO
2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</description><subject>Animals</subject><subject>Blood Substitutes - metabolism</subject><subject>Blood Substitutes - therapeutic use</subject><subject>Drug Evaluation</subject><subject>fluorocarbons</subject><subject>Fluorocarbons - metabolism</subject><subject>Fluorocarbons - therapeutic use</subject><subject>hemorrhagic shock</subject><subject>Humans</subject><subject>Oxygen Consumption</subject><subject>oxygen transport</subject><subject>Papio</subject><subject>polyhemoglobin</subject><subject>Rats</subject><subject>Shock, Hemorrhagic - drug therapy</subject><issn>0196-0644</issn><issn>1097-6760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUhYMotVZ_QnFWoovRm0ySSdyUUnxBQfCxDjPJDUTaTp1kBP-90wfdurqLc849936EjCncUqDy7h2oljlIzq-VuFEAkubiiAwp6DKXpYRjMjxYTslZjF8AoDmjAzLgwIQu2ZBcvqHLLC4WWezqmELqEsb7bLrKurWrEp6TE18tIl7s54h8Pj58zJ7z-evTy2w6z20hIeUVeu9rKUFDWdaeUQ2UFzVwEAheSe8LVVlBNRaqKCqvnVacW1da6rX1rBiRq93eddt8dxiTWYa4uataYdNFU0rGBZO6N4qd0bZNjC16s27Dsmp_DQWzAWO2YMzma6OE2YIxos-N9wVdvUR3SO1J9Ppkp2P_5U_A1kQbcGXRhRZtMq4J_zT8AVyfcJM</recordid><startdate>198508</startdate><enddate>198508</enddate><creator>Gould, Steven A</creator><creator>Sehgal, Lakshman R</creator><creator>Rosen, Arthur L</creator><creator>Sehgal, Hansa L</creator><creator>Moss, Gerald S</creator><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198508</creationdate><title>Red cell substitutes: An update</title><author>Gould, Steven A ; Sehgal, Lakshman R ; Rosen, Arthur L ; Sehgal, Hansa L ; Moss, Gerald S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-aefffb6609077bf2190143b0405e0f86ff38ac519e3833af9d9844cd7c1f9cf23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Animals</topic><topic>Blood Substitutes - metabolism</topic><topic>Blood Substitutes - therapeutic use</topic><topic>Drug Evaluation</topic><topic>fluorocarbons</topic><topic>Fluorocarbons - metabolism</topic><topic>Fluorocarbons - therapeutic use</topic><topic>hemorrhagic shock</topic><topic>Humans</topic><topic>Oxygen Consumption</topic><topic>oxygen transport</topic><topic>Papio</topic><topic>polyhemoglobin</topic><topic>Rats</topic><topic>Shock, Hemorrhagic - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gould, Steven A</creatorcontrib><creatorcontrib>Sehgal, Lakshman R</creatorcontrib><creatorcontrib>Rosen, Arthur L</creatorcontrib><creatorcontrib>Sehgal, Hansa L</creatorcontrib><creatorcontrib>Moss, Gerald S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gould, Steven A</au><au>Sehgal, Lakshman R</au><au>Rosen, Arthur L</au><au>Sehgal, Hansa L</au><au>Moss, Gerald S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Red cell substitutes: An update</atitle><jtitle>Annals of emergency medicine</jtitle><addtitle>Ann Emerg Med</addtitle><date>1985-08</date><risdate>1985</risdate><volume>14</volume><issue>8</issue><spage>798</spage><epage>803</epage><pages>798-803</pages><issn>0196-0644</issn><eissn>1097-6760</eissn><abstract>The two acellular oxygen carriers currently being evaluated as red cell substitutes are hemoglobin solutions and fluorocarbon emulsions. We have shown that both products can maintain normal levels of oxygen consumption, CO
2 production, and circulatory dynamics in primates in the virtual absence of the red blood cell. Although each solution thus satisfies the most important criteria for a red cell substitute, development continues with both products. The clinical trials with the fluorocarbons have been discontinued due to the lack of efficacy of Fluosol-DA — 20% in the setting of acute blood loss. Our current hemoglobin preparation is a polymerized, pyridoxylated product that has a normal oxygen-carrying capacity. Clinical testing must await further evaluation of the safety and efficacy of this product. Alternative uses for both of these oxygen carriers continue to be explored, and may eventually be the area of their greatest utility in the clinical setting.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>4025972</pmid><doi>10.1016/S0196-0644(85)80061-5</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0196-0644 |
ispartof | Annals of emergency medicine, 1985-08, Vol.14 (8), p.798-803 |
issn | 0196-0644 1097-6760 |
language | eng |
recordid | cdi_proquest_miscellaneous_76245269 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Blood Substitutes - metabolism Blood Substitutes - therapeutic use Drug Evaluation fluorocarbons Fluorocarbons - metabolism Fluorocarbons - therapeutic use hemorrhagic shock Humans Oxygen Consumption oxygen transport Papio polyhemoglobin Rats Shock, Hemorrhagic - drug therapy |
title | Red cell substitutes: An update |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Red%20cell%20substitutes:%20An%20update&rft.jtitle=Annals%20of%20emergency%20medicine&rft.au=Gould,%20Steven%20A&rft.date=1985-08&rft.volume=14&rft.issue=8&rft.spage=798&rft.epage=803&rft.pages=798-803&rft.issn=0196-0644&rft.eissn=1097-6760&rft_id=info:doi/10.1016/S0196-0644(85)80061-5&rft_dat=%3Cproquest_cross%3E76245269%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76245269&rft_id=info:pmid/4025972&rft_els_id=S0196064485800615&rfr_iscdi=true |